Supernus Pharmaceuticals (SUPN) Free Cash Flow (QoQ) (2011 - 2026)
Supernus Pharmaceuticals (SUPN) Free Cash Flow (QoQ) (2011 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn |
| 3 | Zoetis | 32.71 Bn | 30.77 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.62 Bn | 23.56 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.18 Bn | 21.03 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.80 Bn | 16.48 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.67 Bn | 12.24 Bn | 785.00 Mn |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 242.31% |
| Dec 31, 2025 | 131.45% |
| Sep 30, 2025 | -206.39% |
| Jun 30, 2025 | 91.86% |
| Mar 31, 2025 | -31.50% |
| Dec 31, 2024 | -17.12% |
| Sep 30, 2024 | 49.94% |
| Jun 30, 2024 | -6.80% |
| Mar 31, 2024 | -15.20% |
| Dec 31, 2023 | 25.95% |
| Sep 30, 2023 | 287.70% |
| Jun 30, 2023 | -138.96% |
| Mar 31, 2023 | 76.14% |
| Dec 31, 2022 | 100.36% |
| Sep 30, 2022 | -80.53% |
| Jun 30, 2022 | 1,794.16% |
| Mar 31, 2022 | -92.30% |
| Dec 31, 2021 | 1,286.45% |
| Sep 30, 2021 | -108.88% |
| Jun 30, 2021 | 27.83% |